0HIY logo

Atara Biotherapeutics LSE:0HIY Stock Report

Last Price

US$0.70

Market Cap

US$71.3m

7D

2.8%

1Y

-76.4%

Updated

28 Mar, 2024

Data

Company Financials +

Atara Biotherapeutics, Inc.

LSE:0HIY Stock Report

Market Cap: US$71.3m

0HIY Stock Overview

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States.

0HIY fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Atara Biotherapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Atara Biotherapeutics
Historical stock prices
Current Share PriceUS$0.70
52 Week HighUS$3.08
52 Week LowUS$0.20
Beta0.71
1 Month Change-12.46%
3 Month Change20.15%
1 Year Change-76.36%
3 Year Change-95.29%
5 Year Changen/a
Change since IPO-98.12%

Recent News & Updates

Recent updates

Shareholder Returns

0HIYGB BiotechsGB Market
7D2.8%1.7%2.2%
1Y-76.4%-27.5%3.7%

Return vs Industry: 0HIY underperformed the UK Biotechs industry which returned -27.5% over the past year.

Return vs Market: 0HIY underperformed the UK Market which returned 3.7% over the past year.

Price Volatility

Is 0HIY's price volatile compared to industry and market?
0HIY volatility
0HIY Average Weekly Movement27.1%
Biotechs Industry Average Movement7.9%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0HIY's share price has been volatile over the past 3 months.

Volatility Over Time: 0HIY's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
2012317Pascal Touchonhttps://www.atarabio.com

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis.

Atara Biotherapeutics, Inc. Fundamentals Summary

How do Atara Biotherapeutics's earnings and revenue compare to its market cap?
0HIY fundamental statistics
Market capUS$71.35m
Earnings (TTM)-US$290.25m
Revenue (TTM)US$4.54m

15.7x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0HIY income statement (TTM)
RevenueUS$4.54m
Cost of RevenueUS$5.73m
Gross Profit-US$1.18m
Other ExpensesUS$289.06m
Earnings-US$290.25m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.85
Gross Margin-26.07%
Net Profit Margin-6,390.31%
Debt/Equity Ratio0%

How did 0HIY perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.